Aspiriant LLC Has $2.26 Million Holdings in Abbott Laboratories (NYSE:ABT)

Aspiriant LLC cut its stake in Abbott Laboratories (NYSE:ABT) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,934 shares of the healthcare product maker’s stock after selling 384 shares during the period. Aspiriant LLC’s holdings in Abbott Laboratories were worth $2,255,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ABT. Intech Investment Management LLC boosted its holdings in shares of Abbott Laboratories by 10.0% in the 2nd quarter. Intech Investment Management LLC now owns 35,323 shares of the healthcare product maker’s stock worth $3,670,000 after acquiring an additional 3,200 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Abbott Laboratories by 4.5% in the second quarter. Thrivent Financial for Lutherans now owns 479,241 shares of the healthcare product maker’s stock valued at $49,799,000 after purchasing an additional 20,480 shares in the last quarter. Frank Rimerman Advisors LLC increased its holdings in shares of Abbott Laboratories by 22,650.7% in the second quarter. Frank Rimerman Advisors LLC now owns 16,608 shares of the healthcare product maker’s stock valued at $1,726,000 after purchasing an additional 16,535 shares in the last quarter. 1832 Asset Management L.P. increased its holdings in shares of Abbott Laboratories by 115.9% in the second quarter. 1832 Asset Management L.P. now owns 161,505 shares of the healthcare product maker’s stock valued at $16,782,000 after purchasing an additional 86,707 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its holdings in shares of Abbott Laboratories by 1.7% in the second quarter. Epoch Investment Partners Inc. now owns 60,703 shares of the healthcare product maker’s stock valued at $6,308,000 after purchasing an additional 988 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $113.45 on Tuesday. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $121.64. The stock has a market capitalization of $196.78 billion, a price-to-earnings ratio of 34.48, a PEG ratio of 2.40 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The business has a 50-day moving average of $114.93 and a 200-day moving average of $112.87.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.08%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s dividend payout ratio is currently 66.87%.

Wall Street Analyst Weigh In

ABT has been the subject of a number of research reports. Barclays raised their price target on shares of Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Oppenheimer initiated coverage on shares of Abbott Laboratories in a report on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price objective on the stock. Sanford C. Bernstein increased their price objective on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Royal Bank of Canada increased their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, Morgan Stanley increased their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $131.57.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.